A peptide aptamer to antagonize BCL-6 function

Area of Science:

• Molecular Biology
• Cancer Research
• Immunology

Background:

• BCL-6 is a crucial transcription factor for germinal center B-cell development.
• BCL-6 dysregulation is implicated in diffuse large B-cell lymphoma, non-Hodgkin's lymphoma, and breast cancer.
• BCL-6 functions as a transcriptional repressor via its N-terminal POZ domain.

Purpose of the Study:

• To identify novel inhibitors of BCL-6 activity by targeting its POZ domain.
• To develop peptide aptamers that specifically disrupt BCL-6 POZ domain interactions.
• To evaluate the therapeutic potential of these aptamers in BCL-6-driven malignancies.

Main Methods:

• Screening a peptide aptamer library for binders to the BCL-6 POZ domain.
• Characterizing the binding interaction of Apt48 with BCL-6 POZ.
• Assessing the functional effects of Apt48 on BCL-6-mediated gene repression using a luciferase reporter assay.
• Evaluating Apt48's impact on B-cell differentiation markers and cytokine-mediated growth arrest.

Main Results:

• Identified Apt48, a peptide aptamer that specifically binds to the BCL-6 POZ domain.
• Apt48 inhibits BCL-6-mediated transcriptional repression.
• Expression of Apt48 increased differentiation markers (CD69, Blimp-1, cyclin D2) in B-cell lines.
• Apt48 restored cytokine-mediated growth arrest in BCL-6 overexpressing cells.

Conclusions:

• A peptide aptamer, Apt48, has been developed that antagonizes BCL-6 function.
• Apt48 disrupts a critical function of BCL-6 required to inhibit B-cell differentiation.
• This study presents a novel strategy for targeting BCL-6 in lymphoma and other cancers.